“The 18% reduction in colorectal cancer incidence was statistically significant, while the 10% reduction in colorectal cancer mortality and 1% reduction in overall mortality were not.”
NordICC randomized 85,179 people and finally tested the procedure America has sold as standard for decades. Only 42% of those invited showed up. Gastroenterologists answered by quoting a 50% mortality cut from a per-protocol analysis that needs heroic assumptions. A naive correction for everyone showing up gives 24%. The specialty that bills for the scope also picked the rosiest number.